The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation

Show full item record



Permalink

http://hdl.handle.net/10138/328474

Citation

Poire , X , Labopin , M , Polge , E , Volin , L , Finke , J , Ganser , A , Blaise , D , Yakoub-Agha , I , Beelen , D , Forcade , E , Lioure , B , Socie , G , Niederwieser , D , Labussiere-Wallet , H , Maertens , J , Cornelissen , J , Craddock , C , Mohty , M , Esteve , J & Nagler , A 2020 , ' The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation ' , American Journal of Hematology , vol. 95 , no. 3 , pp. 282-294 . https://doi.org/10.1002/ajh.25714

Title: The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation
Author: Poire, Xavier; Labopin, Myriam; Polge, Emmanuelle; Volin, Liisa; Finke, Juergen; Ganser, Arnold; Blaise, Didier; Yakoub-Agha, Ibrahim; Beelen, Dietrich; Forcade, Edouard; Lioure, Bruno; Socie, Gerard; Niederwieser, Dietger; Labussiere-Wallet, Helene; Maertens, Johan; Cornelissen, Jan; Craddock, Charles; Mohty, Mohamad; Esteve, Jordi; Nagler, Arnon
Contributor: University of Helsinki, HUS Comprehensive Cancer Center
Date: 2020-03
Language: eng
Number of pages: 13
Belongs to series: American Journal of Hematology
ISSN: 0361-8609
URI: http://hdl.handle.net/10138/328474
Abstract: Monosomy 7 or deletion 7q (-7/7q-) is the most frequent adverse cytogenetic features reported in acute myeloid leukemia (AML), and is a common indication for allogeneic stem cell transplantation (SCT). Nevertheless, -7/7q- occurs frequently with other high-risk cytogenetic abnormalities such as complex karyotype (CK), monosomal karyotype (MK), monosomy 5 or deletion 5q (-5/5q-), 17p abnormalities (abn(17p)) or inversion of chromosome 3 (inv(3)), the presence of which may influence the outcomes after SCT. A total of 1109 patients were allocated to this study. Two-year probability of leukemia-free survival (LFS) and overall survival (OS) were 30% and 36%, respectively. Two-year probability of non-relapse mortality (NRM) was 20%. We defined five different cytogenetic subgroups: the "-7/7q- +/- CK group- designated group1," the "MK group-designated group 2," the "-5/5q- group- designated group 3," the "abn(17p) group- designated group 4" and the "inv(3) group- designated group 5." The 2-year probability of LFS in first remission was 48% for group 1, 36.4% for group 2, 28.4% for group 3, 19.1% for group 4 and 17.3% for group 5, respectively (P <.001). Multivariate analysis confirmed those significant differences across groups. Note, SCT in -7/7q- AML provides durable responses in one third of the patients. The presence of -7/7q- with or without CK in the absence of MK, abn(17p) or inv (3) is associated with a better survival after SCT. On the contrary, addition of MK, -5/5q-, abn(17p) or inv(3) identifies a sub-group of patients with poor prognosis even after SCT.
Subject: COMPLEX ABERRANT KARYOTYPE
ACUTE MYELOGENOUS LEUKEMIA
1ST COMPLETE REMISSION
MYELODYSPLASTIC SYNDROME
WORKING PARTY
POSTREMISSION THERAPY
PROGNOSTIC VALUE
EUROPEAN GROUP
AML
RELAPSE
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
The_impact_of_c ... m_cell_transplantation.pdf 1.788Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record